Original BioMedicals Co., Ltd. (6483) Fair Value & Analysis
Healthcare · TW · Market cap 929M TWD (≈ $29.3M) · ISIN TW0006483001
What is Original BioMedicals Co., Ltd. really worth?
Below-average quality, and trading another 580% above our fair value of 2.06 TWD.
As of Aug 28, 2026, the fair value of Original BioMedicals Co., Ltd. is 2.06 TWD per share against a price of 14.00 TWD, so the fair value sits 85% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Risks
Fair value as of: Aug 28, 2026
From 1 valuation models · updated 9 days ago
Fair value updated Aug 28, 2026, revised from 2.07 TWD to 2.06 TWD (−0.5%) since Aug 13, 2026. Share price −0.4% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (2.58 TWD). The favourable scenario is already priced in.
- Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (1.36 TWD to 2.58 TWD) leaves room in how you read the outcome.
Price vs Fair Value (9 months)
White line = price, green steps = our fair value per fiscal year. As of Aug 28, 2026.
How to read this chart
9‑month range 11.70 TWD – 19.20 TWD · fair‑value band 1.36 TWD – 2.58 TWD · the 14.00 TWD price screens above the 2.06 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Aug 28, 2026.
Analysis
Original BioMedicals Co., Ltd. (6483) currently trades at 14.00 TWD, while our model-based Fair Value estimate is 2.06 TWD, implying the stock looks roughly 579.8% overvalued today. The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.
Trailing-twelve-month revenue stands at 381K TWD. It earns a return on equity of −49.2%. The balance sheet holds a net cash position of 139M TWD. Fundamentals as of Aug 28, 2026
Our scenario range runs from 1.36 TWD (bear case) to 2.58 TWD (bull case); at 14.00 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 27% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −85%, 6483 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when 6483 reaches fair value
Put 6483 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 31 · Market factors (momentum, volatility) 43
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Original BioMedicals Co., Ltd., engages in the development of new drugs without new ingredients in Taiwan. The company develops OBM-A01, for the treatment of acute radiation injury, including nuclear radiation and solar radiation exposed in space; OBM-B01, a cyanide compound drug for protection against toxic gases from fires; and CCM-CL, a cyclic …
Full company description
Original BioMedicals Co., Ltd., engages in the development of new drugs without new ingredients in Taiwan. The company develops OBM-A01, for the treatment of acute radiation injury, including nuclear radiation and solar radiation exposed in space; OBM-B01, a cyanide compound drug for protection against toxic gases from fires; and CCM-CL, a cyclic polypeptide antibiotic; and Iron Dextran, an injection for treatment of iron deficiency. It also provides NE (Vit. C+E); and NE Butorphanol. The company was founded in 2011 and is based in Tainan City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Original BioMedicals Co., Ltd. reported revenue of 381K TWD in FY2025 versus 107K TWD in FY2022, a compound +52.7%/yr. Reported net income was −102M TWD in FY2025.
6483 screens 580% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 609 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,899 | ₹989.50 | −48% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare Original BioMedicals Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Original BioMedicals Co., Ltd. (6483) overvalued or undervalued?
What is the fair value of 6483?
What is the quality score of 6483?
What is the price target for Original BioMedicals Co., Ltd. (6483)?
What is the Original BioMedicals Co., Ltd. stock forecast for 2026?
What is the revenue of Original BioMedicals Co., Ltd. (6483)?
What is the net profit margin of 6483?
Watch Original BioMedicals Co., Ltd. in the live analysis
One click puts Original BioMedicals Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.